Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression

BACKGROUND: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that has improved survival and central nervous system (CNS) outcomes in patients with non-small cell lung cancer (NSCLC) with activating EGFR mutations. However, little is known about the efficacy and safety of combin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Lung Cancer
Autores principales: White, Maya N, Piotrowska, Zofia, Stirling, Kevin, Liu, Stephen V, Banwait, Mandeep K, Cunanan, Kristen, Sequist, Lecia V, Wakelee, Heather A, Hausrath, Daniel, Neal, Joel W
Formato: Artigo
Lenguaje:Inglês
Publicado: 2021
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8205932/
https://ncbi.nlm.nih.gov/pubmed/33610453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2021.01.010
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares